SAMSUNG-ELECTRONICS
4.6.2021 10:02:05 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that it received the industry’s first Triple Standard for carbon, water and waste by Carbon Trust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005166/en/
Samsung was awarded this certification by reducing the amount of carbon emissions, water use, and waste discharge over the past three years at five operations (Giheung, Hwaseong, Pyeongtaek, Onyang and Cheonan) in Korea and four global manufacturing sites in U.S. and China (Austin, Suzhou, Tianjin and Xi’an). This is a huge feat, considering that it is extremely challenging for semiconductor manufacturing companies to meet all three qualifications at once.
“For decades, Samsung has been striving to incorporate environmental sustainability into every aspect of the semiconductor manufacturing process,” said Seong-dai Jang, senior vice president and head of DS Corporate Sustainability Management Office at Samsung Electronics. “We’ll continue to pursue more environmentally sustainable policies across the entire production and supply chain.”
Samsung has been making various efforts in carbon reduction, water resource conservation and recycling, and has been managing these as important sustainability goals.
Samsung’s efforts to reduce its environmental footprint
- Greenhouse Gas : Samsung has been sourcing 100-percent renewable energy for its overseas semiconductor operations in the United States and China since 2019, and the company's continued efforts to reduce its carbon footprint also includes optimizing gas use for etching and deposition processes, as well as developing new catalysts for its greenhouse gas reduction equipment. Through these endeavors, Samsung was able to cut about 1.3-million tons1 of carbon emissions in 2020—about 200 million pine trees would be required to absorb the same amount of carbon2 .
- Water Management : Samsung has been recycling wastewater generated in the process of producing ultra-pure water for equipment such as wet scrubbers and cooling towers. The company has also reduced water usage utilizing its wastewater filtration technology—known as the ‘membrane process’ —to reuse water and optimize manufacturing processes. Equipment operation efficiency has also increased by consolidating wastewater reclamation and reuse systems. As a result, Samsung was able to reuse about 70 million tons of water in 2020, a 12-percent increase compared to 2018~2019, and reduce more than 10 million tons of water usage3 , which is the same amount used for two-million people per month in a metropolitan area in Korea4 .
- Waste Discharge: Samsung has significantly reduced wastewater sludge5 , which accounts for more than 60-percent of total waste generation, by applying alternative materials and optimizing the amount of materials supplied to particular facilities. In addition, by establishing packaging standards for products brought into the line, the amount of waste from over-packaging has also been reduced. Through all these efforts, Samsung reduced a total of 35,752 tons6 of waste discharged in 2020.
Samsung Electronics strives to incorporate environmental sustainability into everything it does. Samsung’s products are thoughtfully designed to minimize the impact on the environment during their entire lifecycle – from planning and manufacturing to consumption and recycling.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
1 The amounts stated are converted measurements based on production levels
2 A 30-year-old pine tree can absorb about 6.6 kilograms of carbon dioxide (CO2) per year (Korea Institute of Forest Science)
3 The amounts stated are converted measurements based on production levels
4 Korea Ministry of Environment (2019)
5 Wastewater sludge is a by-product generated in the treatment process of industrial wastewater or sewage.
6 The amounts stated are converted measurements based on production levels
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
